Clinical efficacy of immunotherapy plus targeted therapy combined with local treatment for unresectable hepatocellular carcinoma
10.3760/cma.j.cn115610-20220929-00559
- VernacularTitle:免疫靶向联合局部治疗不可切除肝细胞癌的临床疗效
- Author:
Weichen ZHANG
1
;
Songfeng YU
;
Tanyang ZHOU
;
Yi ZHENG
;
Haiyan SHI
;
Liang SHEN
;
Longyu CHENG
;
Dongyan WU
;
Jun YU
Author Information
1. 浙江大学医学院附属第一医院肝胆胰外科，杭州 310003
- Keywords:
Liver neoplasms;
Local treatment;
Immunotherapy;
Targeted therapy;
Conversion therapy
- From:
Chinese Journal of Digestive Surgery
2022;21(S1):25-28
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy combined with targeted therapy can benefit the survival of patients with unresectable hepatocellular carcinoma. Atezolizumab combined with bevacizumab has achieved remarkable efficacy in patients with advanced hepatocellular carcinoma, but the efficacy of conversion therapy in patients with unresectable hepatocellular carcinoma still needs more evidences. The authors report the clinical efficacy of a case of unresectable hepatocellular carcinoma with hepatitis B virus related liver cirrhosis who was treated with immunotherapy plus targeted therapy combined with local treatment. Results show a good effect in patient without tumor recurrence after postoperative 9 months.
